Tidutamab Biosimilar – Anti-CD3 epsilon, SSTR2 mAb – Research Grade

Tidutamab Biosimilar – Anti-CD3 epsilon, SSTR2 mAb – Research Grade Introduction

Tidutamab Biosimilar is a novel monoclonal antibody (mAb) that targets two important therapeutic targets, CD3 epsilon and SSTR2. This research grade mAb is designed to have a similar structure and activity as the original Tidutamab, but at a more affordable cost. In this article, we will provide a detailed scientific description of Tidutamab Biosimilar, including its structure, activity, and potential applications.

Structure of Tidutamab Biosimilar

Tidutamab Biosimilar is a recombinant, humanized IgG1 monoclonal antibody. It is composed of two identical heavy chains and two identical light chains, each containing a variable region and a constant region. The variable region of Tidutamab Biosimilar is specific for CD3 epsilon and the constant region is derived from human IgG1. The molecular weight of Tidutamab Biosimilar is approximately 150 kDa.

The three-dimensional structure of Tidutamab Biosimilar is similar to that of the original Tidutamab. It consists of a Y-shaped molecule with two heavy chains and two light chains connected by disulfide bonds. The variable regions of the heavy and light chains form the antigen-binding site, while the constant regions determine the effector functions of the antibody.

Activity of Tidutamab Biosimilar

Tidutamab Biosimilar is a dual-targeting antibody that binds to both CD3 epsilon and SSTR2. CD3 epsilon is a subunit of the T-cell receptor complex and is essential for T-cell activation. By binding to CD3 epsilon, Tidutamab Biosimilar can activate T-cells and enhance their anti-tumor activity. SSTR2, on the other hand, is a receptor for somatostatin, a hormone that inhibits the growth of various tumors. By targeting SSTR2, Tidutamab Biosimilar can directly inhibit the growth of tumor cells.

In addition to its dual-targeting activity, Tidutamab Biosimilar also has a strong binding affinity for both CD3 epsilon and SSTR2. This allows for efficient and specific targeting of these therapeutic targets, leading to enhanced therapeutic effects.

Potential Applications of Tidutamab Biosimilar

Tidutamab Biosimilar has potential applications in the treatment of various types of cancer, including solid tumors and hematologic malignancies. By targeting both CD3 epsilon and SSTR2, Tidutamab Biosimilar can activate T-cells and directly inhibit tumor growth, making it a promising therapy for cancer treatment.

In addition, Tidutamab Biosimilar may also have potential applications in autoimmune diseases. By targeting CD3 epsilon, Tidutamab Biosimilar can modulate the activity of T-cells and potentially suppress the immune response, making it a potential therapy for autoimmune disorders such as rheumatoid arthritis and multiple sclerosis.

Conclusion

Tidutamab Biosimilar is a novel monoclonal antibody that targets both CD3 epsilon and SSTR2. Its structure, activity, and potential applications make it a promising therapy for cancer and autoimmune diseases. As a research grade antibody, Tidutamab Biosimilar provides a more affordable option for researchers and clinicians to study and potentially utilize in their treatments. Further studies and clinical trials are needed to fully explore the potential of Tidutamab Biosimilar in the field of medicine.

Keywords: Tidutamab Biosimilar, monoclonal antibody, CD3 epsilon, SSTR2, therapeutic target, structure, activity, application, cancer, autoimmune diseases, research grade.

ProteoGenix catalogue number PX-TA1565. For research use only.

Target: Tidutamab Biosimilar – Anti-CD3 epsilon, SSTR2 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB, Flow Cyt.

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet

Download the manufacturer safety data sheet (MSDS/SDS)